DR3 Knockout Mouse

Constitutive Knockout

DR3 Constitutive Knockout Mouse Model
This line is cryopreserved and requires cryorecovery.

129;C57BL/6 Background

  • Model #
  • Genotype
  • Nomenclature
  • 14096-F
  • 14096-M
  • Knockout of the tumor necrosis factor receptor superfamily, member 25 Tnfrsf25 (also known as Dr3) gene
  • Dr3 mediates regulation of the cell division cycle.
  • Negative selection and anti-CD3-induced apoptosis are significantly impaired in Dr3-null mice.

Genetic Background:



The Dr3 knockout mouse was developed in the laboratory of Eddie Wang at the Imperial Cancer Research Fund, Lincoln's Inn Fields, London. A DR3 targeting vector, replacing the entire DR3 coding region with a loxP flanked resistance cassette, was transfected into GK129 ES cells. Correctly targeted ES cells were injected into C57BL/6 blastocysts. Chimeric offspring were mated to C57BL/6 mice to yield mice heterozygous for the mutant allele. Heterozygous mice were interbred to generate homozygous Dr3-/- mice. Taconic received embryos from CRT in 2015.


Cancer Research Technology (CRT)



Initial Publication:

Wang et al. 2001. DR3 regulates negative selection during thymocyte development. Molecular and Cellular Biology. 21:3451-61.

Access to this model requires execution of a Limited Breeding Agreement and cryorecovery services to recover the line. Current Limited Breeding Agreement fees for this model are $2,500/year (€2000/year) for nonprofit users and $10,000/year (€8000) for for-profit users. Cryorecovery fees are additional.